Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-08-27
2010-11-16
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S456000
Reexamination Certificate
active
07833997
ABSTRACT:
The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 4762857 (1988-08-01), Bollin, Jr. et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5932566 (1999-08-01), Schnur et al.
patent: 6872715 (2005-03-01), Santi et al.
patent: 7465718 (2008-12-01), Zhang et al.
patent: 2004/0053909 (2004-03-01), Snader et al.
patent: 2006/0205705 (2006-09-01), Ross et al.
patent: 2 106 111 (1993-04-01), None
patent: WO-93/14215 (1993-07-01), None
patent: WO-95/01342 (1995-01-01), None
patent: WO-03/013430 (2003-02-01), None
patent: WO-03/026571 (2003-04-01), None
patent: WO-03/066005 (2003-08-01), None
patent: WO-2005/063714 (2005-07-01), None
patent: WO-2005/095347 (2005-10-01), None
patent: WO-2006098761 (2006-09-01), None
patent: WO 2007/001049 (2007-01-01), None
patent: WO-2007002093 (2007-01-01), None
patent: WO-2007009007 (2007-01-01), None
patent: WO-2008128063 (2008-10-01), None
Clevenger, R. C. et al., “Design, Synthesis, and Evaluation of a Radicicol and Geldamycin Chimera, Radamide”,Organic Letters, 6(24):4459-4462 (2004).
Fritz et al., “Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors,” Infinity Pharmaceuticals, Inc., Presented by Christian Fritz on Oct. 22, 2008 at the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics,” (Geneva, Switzerland, Oct. 21-24, 2008).
Ge et al., “Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90,” J. Med. Chem., 49:4606-4615 (2006).
Guo, W. et al., “Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxireductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition”,Cancer Res., 65(21):10006-10015 (Nov. 21, 2005).
Hostein et al., “Inhibition of Signal Transduction by the Hsp90 Inhibitor 17-Allylamino-17-demethoxygeldanamycin Results in Cytostasis and Apoptosis,” Cancer Research, 61:4003-4009 (2001).
Hu, Z. et al., “Isolation and Characterization of Novel Geldanamycin Analogues”,Journ. Antibiot, 57(7):421-428 (Jul. 2004).
“Infinity Provides Update On Phase 2 Signal-Finding Clinical Study of IPI-504 in Advanced Prostate Cancer,” Infinity Pharmaceuticals, Inc. Press Release, Jul. 14, 2008.
International Search Report dated Apr. 25, 2005 for PCT/US2004/043162.
Kelland, L. R. et al., “DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino, 17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90”,Journ. of the Nat. Cancer Inst., 91(22):1940-1949 (Nov. 17, 1999).
Maroney et al., “Dihydroquinone Ansamycins: Toward Resolving the Conflict between Low in Vitro Affinity and High Cellular Potency of Geldanamycin Derivatives,” Biochemistry, 45:5678-5685 (2006).
Mitsiades, C. S. et al., “Antimyeloma activity of heat shock protein-90 inhibition”,Blood, 107(3):1092-1100 (Feb. 1, 2006).
O'Brien, P.J, “Molecular Mechanisms of Quinone Cytotoxicity,” Chem.-Biol. Interactions, 80:1-41 (1991).
Oh et al., “A single arm Phase 2 trial of IPI-504 in patients with castration resistant prostate cancer (CRPC),” Abstract submitted Oct. 24, 2008, for the 2009 ASCO Genitourinary Cancers Symposium, Orlando, FL, Feb. 26-28, 2009.
Onuoha et al., “Mechanistic Studies on Hsp90 Inhibition by Ansamycin Derivatives,” J. Mol. Biol., 372:287-297 (2007).
Porter, James R, “Synthesis and Biological Evaluation of IPI-504, an Aqueous Soluble Analog of 17-AAG and Potent Inhibitor of Hsp90,” Presentation by James Porter at ACS Meeting: MEDI-210, Mar. 29, 2006.
Schnur, R. C. et al., “Inhibition of the Oncogene Product p 185erbB-2 in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives”, J. Med. Chem., 38:3806-3812 (1995).
Snydor et al., “Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90,” PNAS, 103(46);17408-17413 (2006).
Office action dated Feb. 19, 2009 for U.S. Appl. No. 11/180,314.
Office action dated Jul. 31, 2008 for U.S. Appl. No. 11/180,314.
Office action dated Oct. 26, 2007 for U.S. Appl. No. 11/180,314.
Request for Continued Examination filed Oct. 31, 2008 for U.S. Appl. No. 11/180,314.
Response under C.F.R. Section 1.111 dated Mar. 25, 2008 for U.S. Appl. No. 11/180,314.
Guo, et al., “A Potential Role for NAD(P)H:quinine oxideductase1 (NQO1) in the Mechanism of Action of the Hsp90 Inhibitors Geldanamycin and 17AAG” AACR Annual Meeting, Apr. 2005, vol. 46, 4936.
Miller, et al., “Depletion of the erbB-2 Gene Product p185 by Benzoquinoid Ansamycins,” Cancer Research 1994, 54, 2724-2730.
Mitsiades, et al., “IPI-504: A Novel Hsp90 Inhibitor with In vitro and In vivo Antitumor Activity” Blood (2004) 104:660A.
Oku, et al., “NMR and Quantum Chemical Study on the OH . . . pi and CH . . . O Interactions between Trehalose and Unsaturated Fatty Acids: Implication for the Mechanism of Antioxidant Function of Trehalose” J. Am. Chem. Soc. (2003) 125:12739-12748.
Oku, et al., “Combined NMR and Quantum Chemical Studies on the Interaction between Trehalose and Dienes Relevant to the Antioxidant Function of Trehalose,” J. Phys. Chem. (2005) 109:3032-3040.
Palombella, et al., “Antitumor Activity of IPI-504, a novel Hsp90 Inhibitor in Multiple Myeloma” Blood (2004) 104:312B-313B.
Reigner, et al., “Simultaneous Assay of Pentachlorophenol and Its Metabolite Tetrachlorohydroquinone, by Gas Chromatography Without Derivitation” J. Chromatography (1990) 533:111-124.
Schnur, et al., “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships” J. Med. Chem (1995) 38; 3813-3820.
European Search Report for EP 06773618.1, (2008).
International Search Report for PCT/US2006/027113, (2006).
International Search Report for PCT/US2006/023987, (2006).
International Search Report for PCT/US2008/060063, (2008).
Office action dated Sep. 16, 2009 from U.S. Appl. No. 11/180,314.
Response to Office action dated May 15, 2009 in U.S. Appl. No. 11/180,314.
Fumo et al. “17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in-downregulating mutated, constitutively activated KIT protein in human mast cells.” Blood, 103:1078-1084 (2004) (prepublished online Oct. 9, 2003).
Sydor et al., “Anti-tumor activity of a novel, water soluble Hsp90 inhibitor IPI-504 in multiple myeloma,” Experimental and Molecular Therapeutics 55: Modulation of Protein Stability, Abstract #6160, Apr. 2005.
Adams Julian
Evangelinos Asimina T. Georges
Gao Yun
Grenier Louis
Pak Roger H.
Foley & Hoag LLP
Infinity Pharmaceuticals Inc.
Kifle Bruck
LandOfFree
Analogs of benzoquinone-containing ansamycins and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analogs of benzoquinone-containing ansamycins and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogs of benzoquinone-containing ansamycins and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180682